Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFAEL ABREU

Allopathic & Osteopathic Physicians Family Medicine

NPI
1265769822
CMS profile
12277
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$603.64

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $603.64 19

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFAEL ABREU

NPI 1265769822 · CMS profile ID 12277

Allopathic & Osteopathic Physicians / Family Medicine

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265769822?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFAEL ABREU, NPI 1265769822, CMS profile ID 12277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265769822?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAFAEL ABREU, NPI 1265769822, CMS profile ID 12277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265769822?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAFAEL ABREU, NPI 1265769822, CMS profile ID 12277, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1265769822?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $603.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $14.2612/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708403135 CMS
Teva Pharmaceuticals USA, Inc. $15.6011/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697769415 CMS
Sunovion Pharmaceuticals Inc. $3.2410/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688136899 CMS
Teva Pharmaceuticals USA, Inc. $16.2810/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697768281 CMS
Shire North American Group Inc $15.8909/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637777005 CMS
Ethicon US, LLC $21.3909/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648732791 CMS
Teva Pharmaceuticals USA, Inc. $21.9808/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697828385 CMS
Teva Pharmaceuticals USA, Inc. $19.3707/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697810919 CMS
Janssen Pharmaceuticals, Inc $15.4007/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658247985 CMS
Novartis Pharmaceuticals Corporation $117.8807/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659102893 CMS
Teva Pharmaceuticals USA, Inc. $18.4407/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697716557 CMS
Janssen Pharmaceuticals, Inc $16.3806/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658247979 CMS
Teva Pharmaceuticals USA, Inc. $17.9204/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697821101 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $103.2904/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625142765 CMS
Janssen Pharmaceuticals, Inc $17.6904/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658247975 CMS
Gilead Sciences, Inc. $14.5704/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681467819 CMS
Janssen Pharmaceuticals, Inc $16.4403/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658247969 CMS
Novartis Pharmaceuticals Corporation $116.6402/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659102889 CMS
Sunovion Pharmaceuticals Inc. $20.9802/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688136897 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $603.64 19
PY2020 $165.04 10
PY2021 $374.56 15
PY2022 $172.11 5
PY2023 $340.05 13
PY2024 $765.65 18
PY2025 $438.74 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $125,091.79 77
PY2024 Principal investigator $287,947.99 115
PY2023 Recipient $300.00 1
PY2023 Principal investigator $3,667.40 2
PY2022 Recipient $300.00 1
PY2022 Principal investigator $49,466.88 5
PY2021 Recipient $20,166.46 2
PY2021 Principal investigator $24,617.76 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bausch Health US, LLC $166.00 12/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846144
Principal investigator 1 Bausch Health US, LLC $1,486.00 11/06/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846139
Principal investigator 1 Bausch Health US, LLC $1,486.00 11/06/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846149
Principal investigator 1 Bausch Health US, LLC $2,343.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845957
Principal investigator 1 Bausch Health US, LLC $2,343.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845960
Principal investigator 1 Bausch Health US, LLC $1,388.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845964
Principal investigator 1 Bausch Health US, LLC $1,486.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845973
Principal investigator 1 Bausch Health US, LLC $2,343.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845984
Principal investigator 1 Bausch Health US, LLC $2,343.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846026
Principal investigator 1 Bausch Health US, LLC $1,486.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846033
Principal investigator 1 Bausch Health US, LLC $1,486.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846038
Principal investigator 1 Bausch Health US, LLC $2,343.00 09/03/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846046
Principal investigator 1 Bausch Health US, LLC $955.00 07/25/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845951
Principal investigator 1 Bausch Health US, LLC $846.00 07/25/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845954
Principal investigator 1 Bausch Health US, LLC $1,275.00 07/25/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845977
Principal investigator 1 Bausch Health US, LLC $1,895.00 07/25/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846009
Principal investigator 1 Bausch Health US, LLC $422.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845947
Principal investigator 1 Bausch Health US, LLC $1,823.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845969
Principal investigator 1 Bausch Health US, LLC $1,823.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845980
Principal investigator 1 Bausch Health US, LLC $1,823.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845989
Principal investigator 1 Bausch Health US, LLC $422.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845994
Principal investigator 1 Bausch Health US, LLC $1,823.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846016
Principal investigator 1 Bausch Health US, LLC $1,486.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846021
Principal investigator 1 Bausch Health US, LLC $1,823.00 07/23/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846030
Principal investigator 1 Bausch Health US, LLC $422.00 07/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845998
Principal investigator 1 Bausch Health US, LLC $1,486.00 07/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846002
Principal investigator 1 Bausch Health US, LLC $422.00 07/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846007
Principal investigator 1 Bausch Health US, LLC $1,722.00 07/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846012
Principal investigator 1 Bausch Health US, LLC $422.00 07/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846041
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846062
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846071
Principal investigator 1 Bausch Health US, LLC $2,343.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846086
Principal investigator 1 Bausch Health US, LLC $422.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846091
Principal investigator 1 Bausch Health US, LLC $2,343.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846100
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846114
Principal investigator 1 Bausch Health US, LLC $1,722.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846118
Principal investigator 1 Bausch Health US, LLC $422.00 06/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846135
Principal investigator 1 Bausch Health US, LLC $1,494.00 05/14/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846074
Principal investigator 1 Bausch Health US, LLC $422.00 05/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846078
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846096
Principal investigator 1 Bausch Health US, LLC $422.00 05/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846103
Principal investigator 1 Bausch Health US, LLC $422.00 05/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846110
Principal investigator 1 Bausch Health US, LLC $1,388.00 05/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846121
Principal investigator 1 Bausch Health US, LLC $1,823.00 05/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846126
Principal investigator 1 Bausch Health US, LLC $1,779.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846051
Principal investigator 1 Bausch Health US, LLC $422.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846054
Principal investigator 1 Bausch Health US, LLC $422.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846057
Principal investigator 1 Bausch Health US, LLC $1,779.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846068
Principal investigator 1 Bausch Health US, LLC $1,779.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846082
Principal investigator 1 Bausch Health US, LLC $1,779.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846106
Principal investigator 1 Bausch Health US, LLC $1,779.00 04/02/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846129
Principal investigator 1 Bausch Health US, LLC $422.00 03/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845862
Principal investigator 1 Bausch Health US, LLC $1,722.00 03/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845867
Principal investigator 1 Bausch Health US, LLC $422.00 03/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845906
Principal investigator 1 Bausch Health US, LLC $422.00 03/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845922
Principal investigator 1 Bausch Health US, LLC $422.00 03/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845925
Principal investigator 1 Bausch Health US, LLC $422.00 03/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845935
Principal investigator 1 Bausch Health US, LLC $1,388.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845844
Principal investigator 1 Bausch Health US, LLC $1,722.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845849
Principal investigator 1 Bausch Health US, LLC $1,388.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845858
Principal investigator 1 Bausch Health US, LLC $1,722.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845870
Principal investigator 1 Bausch Health US, LLC $1,722.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845874
Principal investigator 1 Bausch Health US, LLC $1,388.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845878
Principal investigator 1 Bausch Health US, LLC $1,722.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845887
Principal investigator 1 Bausch Health US, LLC $1,388.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845892
Principal investigator 1 Bausch Health US, LLC $1,388.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845897
Principal investigator 1 Bausch Health US, LLC $1,722.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845902
Principal investigator 1 Bausch Health US, LLC $1,722.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845914
Principal investigator 1 Bausch Health US, LLC $422.00 02/07/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845943
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,714.79 01/22/2025 Non-covered Recipient Entity
SUPERIOR ASSOCIATES IN RESEARCH LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185554741
Principal investigator 1 Bausch Health US, LLC $422.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845840
Principal investigator 1 Bausch Health US, LLC $422.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845853
Principal investigator 1 Bausch Health US, LLC $1,779.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845882
Principal investigator 1 Bausch Health US, LLC $422.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845909
Principal investigator 1 Bausch Health US, LLC $422.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845918
Principal investigator 1 Bausch Health US, LLC $422.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845931
Principal investigator 1 Bausch Health US, LLC $422.00 01/08/2025 Non-covered Recipient Entity
Superior Associates in Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224845938